A multiple targeting rapamycin and SS31 conjugate enhances ischemic stroke therapy

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Cerebral ischemia-reperfusion injury requires drugs targeting multiple pathways for effective treatment.
• Developing multi-target cytoprotectants is crucial for comprehensive protection.

Purpose of the Study:

• To develop RS31, a novel multi-target cytoprotectant combining SS31 and rapamycin.
• To evaluate RS31's efficacy in mitigating oxidative stress, inflammation, and blood-brain barrier damage.
• To investigate RS31's therapeutic potential for ischemic stroke.

Main Methods:

• RS31 synthesized via click chemistry.
• In vitro testing for reactive oxygen species (ROS) scavenging and anti-inflammatory effects.
• In vivo assessment using a transient middle cerebral artery occlusion/reperfusion mouse model.

Main Results:

• RS31 demonstrated significant ROS scavenging and anti-inflammatory properties.
• RS31 showed a 4-fold higher concentration in ischemic brain regions, reducing infarction and improving neurological function.
• RS31 effectively lowered malondialdehyde (MDA) and increased superoxide dismutase (SOD) activity.

Conclusions:

• In vivo delivery of RS31 is a viable therapeutic strategy for ischemia-reperfusion (I/R) injury.
• RS31 offers a promising multi-targeted approach for treating inflammatory diseases and conditions with excessive ROS production.
• This study provides a framework for developing advanced multi-target drugs.